Soleus Capital Management L.P. Makes New $19.82 Million Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Soleus Capital Management L.P. purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 144,000 shares of the biotechnology company's stock, valued at approximately $19,824,000. Ascendis Pharma A/S accounts for 1.2% of Soleus Capital Management L.P.'s holdings, making the stock its 24th largest position. Soleus Capital Management L.P. owned about 0.24% of Ascendis Pharma A/S at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ASND. RA Capital Management L.P. boosted its holdings in Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock valued at $1,392,221,000 after acquiring an additional 402,316 shares during the period. Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S by 2.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock valued at $702,538,000 after purchasing an additional 114,167 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after purchasing an additional 39,309 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Ascendis Pharma A/S by 4.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after purchasing an additional 193,688 shares during the last quarter. Finally, Capital International Investors increased its stake in shares of Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after buying an additional 753,859 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ASND. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Evercore ISI increased their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Morgan Stanley raised Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $180.00 to $250.00 in a research note on Monday, May 5th. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Finally, Royal Bank of Canada boosted their price objective on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and a consensus target price of $216.07.

Ascendis Pharma A/S Trading Up 0.0%

Ascendis Pharma A/S stock opened at $157.60 on Monday. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The company has a market capitalization of $9.61 billion, a price-to-earnings ratio of -22.20 and a beta of 0.41. The business's fifty day simple moving average is $157.15 and its two-hundred day simple moving average is $142.64.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. On average, equities research analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.